Glooko Showcases EndoTool Glycemic Management Platform at Hospital Medicine Conference

According to a recent LinkedIn post from Glooko, the company plans to have its team present at the Society of Hospital Medicine Converge Conference from March 29 to April 1. The post highlights a focus on the EndoTool Glucose Management System, developed by Monarch Medical Technologies, which is described as a Glooko company.

The LinkedIn post suggests that EndoTool is positioned as a tool to help hospitals shift from reactive, uniform insulin protocols toward more proactive, data‑driven glucose management. It also links this positioning to supporting hospitals in meeting newly required Centers for Medicare & Medicaid Services, or CMS, reporting guidelines.

For investors, the emphasis on CMS reporting alignment and glycemic safety points to potential demand drivers in the inpatient diabetes‑management and clinical decision‑support segments. If EndoTool gains traction as a preferred solution for compliance and quality improvement, it could strengthen Glooko’s recurring revenue opportunities and deepen its integration within hospital workflows.

Participation in a major hospital medicine conference may also signal an effort to expand Glooko’s reach among hospitalists and health‑system decision makers, supplementing its existing presence in ambulatory and chronic‑care settings. Over time, broader adoption of EndoTool could enhance Glooko’s competitive position in the digital health and glucose‑management market, particularly as regulatory and quality‑reporting pressures increase.